SecBot SecBot

SRRK

Scholar Rock Holding Corp
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001727196 Biotech & Drug Discovery
$41.49 −0.47 (−1.12%)
Oct 23 4:00 PM ET · prev $41.96
Market cap
$5.1B
Mid cap
Consensus
Buy
92% Buy or better · 24 analysts
Median target
$71.50
+72% · range $58.00–84.00
Next earnings
Nov 10
in 15 days
1 year
+39.8%
from $29.68 · Oct 24
30 days
−14.6%
from $48.61
52-week range
$27.99–60.04
−31% from high · low Nov 5
Avg volume 20D
1.82M
Oct 21 spike 4.60M
Short interest
22.72M
≈18.7% of shares · +17.1%
Days to cover
9.3
at average volume
Insider net
-$4.5M
0 buyers · 10 sellers · since Dec 11
New fund stakes
2
Q2 2026 13F · 1 exit
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Scholar Rock announced FDA approval of ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA) in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    10 insiders sold $4.5M.

  • InstitutionsBULLISH

    Q2 2026: 46 added (2 new), 14 trimmed or exited. Largest new: Massachusetts Financial Services /Ma/ $143.4M, Qube Research & Technologies $25.5M.

  • AnalystsBULLISH

    22 of 24 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +17.1% to 22.72M shares. 9.3 days to cover, ≈18.7% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
1
exit
$168.9M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD9,494,084$522.2M
Orbis Allan Gray LtdADD5,933,533$326.3M
NORGES BANKADD2,769,910$152.3M
GEODE CAPITAL MANAGEMENT, LLCADD2,753,787$151.5M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/NEW2,607,348$143.4M
JENNISON ASSOCIATES LLCTRIM2,358,587$129.7M
ADAGE CAPITAL PARTNERS GP, L.L.C.DOUBLED1,731,402$95.2M
MORGAN STANLEYDOUBLED1,538,776$84.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

24 analysts
Buy 92% rate it Buy or better
Strong Buy9Buy13Hold2Sell0Strong Sell0
12-month targets · 16 analysts

Price is below the lowest target. Median implies +72%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 24, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 21, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Sep 15, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Sep 15, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Sep 15, 2026Jefferies
MAINTAIN
MAINTAINBuy
Sep 15, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$4.5M
sold · 10 insiders
DateInsiderTypeValue
Sep 24, 2026
Woods Keith
Chief Operating Officer
GIFT48,034 sh
Sep 21, 2026
Hallal David
Chief Executive Officer
GIFT36,652 sh
Jul 1, 2026
FLIER JEFFREY S.
Director
SELL$79.7K
Jul 1, 2026
Reed Joshua
Director
SELL$51.5K
Jul 1, 2026
FLIER JEFFREY S.
Director
SELL$83.9K
Jul 1, 2026
Reed Joshua
Director
SELL$112.6K
Jul 1, 2026
FLIER JEFFREY S.
Director
SELL$823.14
Jul 1, 2026
Peng Katie
Director
SELL$1.2K

Earnings setup

Estimates
Nov 10
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
22,722,119
shares short
+17.1%
vs prior settlement
9.3
days to cover
≈18.7%
of shares outstanding
Trading halts
Sep 11, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Other
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inve
Sep 24, 2026 Insider
Woods Keith gifted 48,034 shares
Chief Operating Officer
Sep 21, 2026 Insider
Hallal David gifted 36,652 shares
Chief Executive Officer
Sep 15, 2026 SEC
Scholar Rock filed an 8-K to correct an error made during the September 14 investor call announcing FDA approval of…
8-K — Impact 3/10
Sep 14, 2026 SEC
Scholar Rock announced FDA approval of ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA) in patients aged…
8-K — Impact 8/10
Sep 11, 2026 Event
ISEMBYLD
Original Approval — Type 1 - New Molecular Entity — INJECTABLE
Aug 6, 2026 SEC
Scholar Rock reported Q2 2026 results in line with consensus: EPS of -$0.84 (0.3% beat vs -$0.84 consensus) and zero…
8-K — Impact 5/10
Jul 1, 2026 Insider
FLIER JEFFREY S. sold 1,470 shares
Director @ $54.24 ($79.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
SRRK Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 30, 2026
Press release
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors…
Sep 30, 2026
FDA decision date
PDUFA: SRRK — apitegromab in spinal muscular atrophy (SMA) — 2026-09-30
FDA target action date 2026-09-30 for SRRK (Scholar Rock Holding Corp). Drug: apitegromab. Indication: spinal muscular atrophy (SMA). PDUFA target…
Sep 11, 2026
Trading halt
Halt Resumed: SRRK — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-11T21:07:36.000Z | Resumed 2026-09-11T22:45:00.000Z
Sep 11, 2026
Trading halt
Trading Halt: SRRK — T1 (News Pending)
Scholar Rock Holding Corp CM | Market: NASDAQ | Code: T1 — News Pending
Sep 11, 2026
Trading halt
Trading Halt: SRRK — T2 (News Released)
Scholar Rock Holding Corp CM | Market: NASDAQ | Code: T2 — News Released

SecBot reports

9 filings · 1 bullish · 3 bearish · 2 mixed · 3 neutral
All SRRK filing & press-release reports (9)